THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 5 APRIL 2021

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
CONTENTS
Pag8
Legal ar￿ admirFistrative infomatic
Trustees, report
Independent examin*s report
Staternent of finanoal actIv￿eS
Balance sheet
Slatem8nt of cash flows
Notes to th& financaal statem8nts
10-15

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
LEGAL AND ADMINISTRATIVE INFORMATION
Reference and administrative infomknition
OffiGial charlty name
The Loma and Yuti Chemajovsky BK)medical
Research Foundalion
Charlty Registration number
1184405
Registered offlce
The Chemajovsky FoundatK)n
PO Box 1198
Whr15table
CT5 9DW
Trustees
Yuti ChernaN)¥sky PhD FRCP
Loma Chemaiovsky PhD
Paul PeterTak MDPhD
Admlnlstrators and legal ad¥lser5
Cripps Pemberton Greenish
Number 22
Mount EFthraim
Tunbridge Weus
Kent
Bankers
Coutts & Co
440 Strand
London
WC2R (X)S
Independent Examiner
steven Wake￿d ACA
Dixon WILgJn Charterered Accrwntants
22 Chancery lane
Lond
WC2A1 LS
The trustees are ap￿inted in a¢cordance w&th the terrns of Ihe Trust deed dated 9 July 2019
and have the appyopriate knowledge and expefase to manage arKI administer the Charity. The
trustees have complied with the guidance iwed by the Charity Commiss￿)n. The charity does not
mak8 use of voluntser5.

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
TRUSTEES. REPORT
For the year ended S April 2021
Report of the trustsps for the financlal year ended 5 Aprll 2021
The trustees present their report and the financial statements of the tharity￿ the period 10 5 April 2021.
The financial statements have been prepared in accordance ￿ryth the aco)unting policie5 set out in note 1 to
the finanaal statements and comply with the thanvs Trust Deed, the Charities Act 2011 and the Statement of
Recommended Practi￿.. Accounting and RepoTting by Charities (FRS 102 SORP 2019).
Objectives and a¢tiVStie5
Under the tems of the original TnJst Deed, the trustees have tJiscretN)n to PrOTr￿le, advance and support
charities, charitable ￿ganiSatiOns. charitable WTF￿ and charitable (xuses induding bLrt not limited to:
The pTolection and promotion of the health of the FMJtAic by Ihe pyovision of grants to support biomediLxI
research in the fields of auloimmunity. inflammation. irrfecti(MJS diseases and ageing especially focussed on
the development of practical ap￿iCal￿nS in the fc￿ of new targeled treatmen1&
The trustees must use the income arbj may use the capta of the charity in promoting the obieclives.
The trustees, having regard to the Public Benefft Guidance published ty the Chanty Commission in
accordance with Section 17 of the Charities Act 2011. consder that the purposes and activities of the charity
satisfy the requirements of the public benefft te* sel wt in section 4 of the same ACL
The trustees have paid due reganj to guidan￿ isgJed by the Charity Commission in deciding what activities
the L*arity should undertake.
Review of the year
Following th¢ public launch on 23rd Oct¢tsr 2019. a wblic (all for PhD sbjdentships was announced
requesting Qlaritable organisations to aPFty for funding fc4lowing indeFen¢Jent peer review. the t￿￿tee$
reviewed 28 applications and those to fund 7 grants based uwn remit. scientific quality, innovation and value
for money. The to￿ cost ¢)ver the Idl duration of the grants was £785.089. The start dales of some of the
grants were delayed because ofthe impact of Covid.
Instalments for the grants awarded in the 5 Aprd 2021 year have been paid in accordan￿ with the
agreements reached wrth the d￿ee.
The Covid pandemic nerEssitated that al meeti￿S of trustees and outside organisatt0￿ were held virtualy
and the pandemic dominated much of Ihe year. The grant wev1￿S￿ awarded to the British Society for
Immunology {BSI) to communicate ab￿t CoMd to scientists, public and policy makers allowed a series of
webinars to take ptace with attendance of an average of over 1000 with the most wpular drawing over 2000
people. Sir Patiick Vallance. UK G)vemment Ch￿f Saentific Advisor requested briefings for SAGE from a
Cowd Task Force set up by the BSI and oral and written evidence was provtded to the House of Commons
Select Committee on Science and Technology irNuiry into Gbbal Disease Oulbreaks.
During the year the FoundatiC￿ ente￿d irrto discussi￿$ Connect Immune Re5earc*. a gnjup of medical
research charities comprising of Versus Arthritis, the Multiple Sderosis Soaety and Juvenile Diabeles
Research Fund to explore ways of w0￿1ng tr￿jether to furnl research aimed at developing new treatrnents
eGross autoimmune diseases.
In support of the development of the Autoimmune Transktijnal Research Initiative. the Foundation agreed to
part fund a post at the BSI for £15.000 for 12 m￿thS to faalitate and drive the initiative.
Incoming resources for the period amounted to £717,948. Reserves wll be maintained to Provide fvlure
incoming resourc￿ and awarded as granls when arwriate charitable institutions and causes are identified
or when Costs become payable.

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
TRUSTEES. REPORT
For the year ended S April 2021
Structurej govemance and management
The charity is an uninGorporated registered tharity. cO￿trU￿ed urKkr a Trust Deed dated 9 Jufy 2019. The
trustees h￿d the capitsl and income oflhe charitys Tnjst Fund uwn trust to apply the inco￿￿ and. as far as
may be necessary, the Capit￿ for the purposes set out in dause 22 of the Ttust Deed.
The minimum number of trustees required by the Trust Deed is 3 and the maxirrnjm is 5. Futur8 tnjstees must
be appointed by resolution of the trustees and must h(Ad office for al le8St three years from the date of th6ir
appointment. As required by the Trust Deed. the trustees meet no less than tsVI￿ a year. Except where
otherwlse provided, every issue may be detemiined by a simpte majority of the votes cast at a meeting of the
trustees but a resolution which is in writing and SHJned by all the tnjstees is as valid as a resolution passed at
meellng. For this purpose the resolution may be contained in mDre than one d(￿rne￿t ar￿ vAll be treated
as passed following receipt of th8 necessary written appruval.
Every trustee has one vote on each issknE. In the event of a tie. the c*alm￿n shall hav8 the deciding vote.
The trustees have not adopted any poliues ￿ wocedures for the induction and training of trustees.
RosgTVOS poIi¢y
It is the trustees, pdicy not lo ￿aIn r￿￿e$ as the charitys overheads are bw.
Plan$ for the future
Ouriro the coming financial year 2021122 the tnjstees io SUFPOrt the PhD projects awarded from the first
The trustees wll develop further tI￿AUtr)1MrnUne Reseath Inibative with tharity partners which aims to use
common pathological Pro￿sseS in autoimmune disease5 as taryJets to develop novel theratpeutics that can
be beneficial aGross many diseases. An intematicnal suentific experi meeting i8 planned for 5th May 2021 to
aid priority setting for translational research folknillg brdi[￿$toMlIrQ by leaéers in the field.
It i8 aimed to have a ￿ phased grant support with initial funding of competitive pilot grants to provide pr￿f of
principle. On ¢￿pletion of the iylot st￿lieS, the most promI￿n9 wll be selected for fvrther investment
The charity will expl￿? avenues of CL4latx)ration with other medical research tharfties in other ￿8$ wth an
aim of building overdrching programmes of translation￿ researL* ac•)ss multith disciptine*
Achievements and performance
The tnJstees' overall investrnent obiecbve as Stated ￿ the inveslment management agreement is to maintain
multi-asset portfolio and achieve 8 balan￿ of Inc(￿ and tapital growu). The charity does operate an ethical
investmerrt poliGy.
The performance of the Trust investmenl kKJrtFofio is ¢c￿￿dered al regular intervaLs with the investment
manager and is benchmarked against various market iTrJices (Ind￿￿1ng the FTSE WMA Stock Market
Balanc￿1 Index) to ensure that the funds held are perfLYmin9 well. This manager. which is regLdated by the
Financial Conduct Authority in the United Kingdom, manages the investments within the restrictions set out in
the inwestrnent management a9￿ernent. Any issues are addressed with the tr￿tte•S as and when they arige.
The trustees were satisfied with the perforrnance of the •ivestments during the pemé. Investments at the
pericKJ end had a market value of £1.717.865.
Risk rnanagernent
When making decisions, the tnjslees assess the risks to which the chaThty might be exposed. The truslees
cary out due diliger￿ on charitsble iT￿blUtIOnS before grants are made and document all major decisions.
As part of the grant making process. the irustees agree to folluw up with the d(mee to ensure that fvnds have
been applied for the agreed purpose. This eoukl be by way of a prow reporL peTro￿l visit by on¢ of the
trustees or completion of arl evenL t>onation receipts are cthined from each th)nee.

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
TRUSTEES. REPORT
For the year ended 5 April 2021
statement of responslblllties
The trustees ar¢ ￿sponsible for preparing Ihe Trustees Report and the financial ststeff*nts in accordance
with applicable law and United Kingdom Accounting Stsndards (United lQngdom Generally Accepted
Accounting Practice)-
The law applKxble to charities in ErKJland and Wdes requires the trustees to prepare finanaal ststements for
each finanaal year whic* give a true and fair view of the state of affairs of the charity and of the incoming
resources and application of resources of the charity forthat year.
In preparing these finanaal statements. the ITUStees are required to:
- select suitable accounting p)li¢ies and tr*n apply them ￿￿Stently.
- obs8rv8 the methods and prinoples in the Charities SORP.
- make judgements and estimates that are reasonat4e and pr￿lent
Stale whether applicable accounting standards have been folkjwed. subject to any material departUTes
dIsd￿ed and explained in the statemerts" and
prepare the financial statements on Ihe g(Mng cOr￿M basis unless it is inappropriate to presume that the
charity will contirsue in operation.
The trustees are restK)nsible for keeping s¥Jifiaent accounting reccKds that disclose with reasonable ac¢ur8¢y
al any time the financial wsition of the charity and an3￿? tham to ensure that the financial slatam8nts comply
with the Chartiies Act 2011. the Charity (A(tounts and Reports) Regulations 2008 and the provisions of the
trust deed. They are also responsitrAe for safeguarding the assets of the charity and hence for taking
reasonable steps for the prevention and detection of fra¥Jd and other irregularities.
Dls¢losure of information lo Independent Examln
In so far as the trustees are awa￿, at the time of approving our tru5tees' gnwal ￿pOrt..
- there is no relevant inftjrnwtion. being infornbon needed by the independent examiner in connection with
preparing their report. of which the charivs independenl examiner is unaware: and
the trustees, having made enquiries of fellow trustees arKJ the charivs independent examiner that they
ought lo have individualfy taken, have eadi taken all steps that Ihey are otrAiged to take as trustees in order to
make themselves aware of any relevant indepeTvJent exarnination infr*mation and to establish that the
independent examiner is aware of that infomialion.
Yuti Chemajovsky
For and on behalf of the trustees

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 5 APRIL 2021
Independent examinerfs report to the trustees of tho Chernaiovsky Foundatlon
I report lo the trusiees on my examination of the accounts of the TTUSt for the year ended 5 N)ri12021.
Responsibilities and basis of report
As the charity trustees of the Trust you are resps)nsitAe the preparation of the ac￿Unts in accordanc8
with the requiremenls of the Charities Act 2011 fthe Acf). You are satisfied that an audit is not required
for this year under charity law and that an irKlependent examination is needed.
I report in respect of my 8xaminakn.on of the Tru5Vs a(￿Unts carried out under se¢tion 145 of the 2011
Act arKJ in Carrying out my examination I have followed all ts aprAicable Directions gwen by the Charity
Commission under section 145 (5) Ibl of the Art
An independent examination chjes rK)t involve gathering all the evidence th8t would be required in an
audit and eonsequently does tK>t eA)ver all the matters that an audttor u)nsiders in giving their opinion on
the accounts. Thè planning and Conduct of an audil goes beyond the limited assurance thal an
independent examination can provide. Consequenyy. l express no opinion as to whether the accounts
present a 'true and fair view and my report ￿ limited to those specffic matters set out in the independent
examiners statement
Ind8pendent exarninerfs ststsment
l am qualified to undertake the examination by being a qualffied member of the Institute of Chartered
Acc(wnlants in England ar￿ Wales.
I have completed my examination. I confimi that no material matters have come lo my attentK)n in
connection with Ihe examination givbng me cause to believe that in any material resped:
1- accounting records were rK)t kept in resFect of the Trusi as required by section 130 of the ACL.
2 - the eexounts do not aCC￿d wbth those rec(¥ds', or
3 - the accounts th) not comply the apF4i¢at4e requirements 0￿cerning the form and content of the
ac(yJunts set out in the Charities (Accounts aThJ Reports) Regulations 2008 other than any requirement
that the accounts give a Irue and fair whidi is not a matter o)nsidered as part of an independent
examination.
4 - the accounts have nol been prepared in accordanG8 with the methods and prin¢iFles of the Statement
of Recommended Practice for accounting and reporting by tharities applicable to charits'es preparing their
accounts in accordance with the Financad Reporting Stsndard applicable in the UK and Republic of
Ireland (FFiS 102).
I have no concems and have come auoss no matters in connection wtih the examination to which
attention shoutd be drawn in or(kr to enable a prrser understanding ofthe accounts to be ￿a¢he￿.
STEVEN WAKEFIELD ACA
Dixon Wilson
22 Chancery Lane
London
WC2A 1 LS
Dale.. 5 Fobruary 2022

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
For the year ended 5 Apn"12021
2021
2020
me and endow
Investmenl In￿Me
Royalties
21,789
5.891
696.158 2.303,600
Total income
717.947 2,309,491
endlture on:
Raising funds
1,230
Charitable actiV￿eS
803,340
26,678
T<)lal expendiiurn
803,827
27.908
Net gains1{ losses) on investments
84,433 (107,2691
Net (expenditure)lincome
11.44n 2.174.314
Re¢onciliatlon of funds
Funds brought fwward
2.174.314
Funds carried forwanl
2,172.867 2.174,314

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
BALANCE SHEET
AS AT 5APRIL 2021
2020
Flxed assets
Investments
Current assets
Debtors
Cash at bank and in hand
1.717.865
1,045,006
351,522
854.595
459,000
678,708
1.2(6,117
1.137.7Q8
Creditors: amounts falling due within
onè y•ar
{751.115)
(8,4(M))
Net current assets
455,002
1.129.308
Total assets less current liabilities
2,172,867
2.174,314
The Funds ol the Charity
Unrestrfcled fvnds
2.172,867
2,174,314
2.172.867
2,174,314
The finan¢ial statements on pages 7 to 15 were approved by the Truslees on 412122
an
igned on their behalf by..
Yub Chemaiovs
Trustee

THE LORNAAND YUTI CHERNAIOVSKY BIOMEDICAL RESEARCH
FOUNDATION
STATEMENT OF CASH FLOWS
for the year ended 5 April 2021
2020
Net m0￿M•nt in
(1,44n
2,174,314
Less
Income frorn 1nveslrr￿rrts
(21,790)
(5.8911
Income froTn Royalties
(696.158)
(2,303.6001
Net ￿SSeS on inyestsnents
(84.433)
107,269
Decrease in debtors
107.478
1459.Cm)
Increase in creditors
742.715
8.400
(478.5081
Not cash used In operaung activltles
dividends and interest
717.948
2.309.491
FKoGeeds from Sale of investments
1.012.595
31.
purchase of investments
(1.601.021)
(1,183,965)
129.522
1,157216
Net cash used by Ilnanclng actlvities
change in Cash and eash equNalents
cash and cash equivalents brcwght forward
ehanges in cash value due to exchange rate
movements
cash and cash equNalents ¢arried forward
175.887
678,708
678.708
67&708

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
For the financial year ended 5 Apnl 2021
ounting PDliGies
The principal accounting wlicies applied in Ihe preparati)n of Ihese financial ststements are set out below.
These polictes have been consistently applJ¢d to all the years presented. unless otherwise staled.
The finanaal statements have been prepared under the historical cost convention with itgms recognised at
cost or transaction value unless othetwtse ststed in Ihe relevant notes to these accounts.
The financi81 staternents have been prepared in accordance wth ￿ Statement of Recommended PTactice:
Account and Reporting by Charities preparing their armunts in accordance ￿th the Financial Reporting
standa￿ applicable in the UK and Republic of Ireland {FRS102) effectwe on 1 January 2019. the FinancAal
Reporlng Standard applicable in the UK and Republic of Irdand {FRS 102} and the ChariliesAcl 2011.
The Trust constiltstes a public ber￿fft entrty a$ defin￿ by FRS 102.
1.1 Going concern
The trustees consider that there are no material uncertainties about the Trust's ability to continue as a
gO￿g concern, and that there are no key aSSump￿nS that affect items in the aLxounts.
1.2 Funds structure
The ¢h?rity has an unrestrthd fund created by the assignment of royaltks and the income of the Trust is
unrestricted. the lerms of the TrLESt dlow the (aixtsl of the fvnd to be spent rf trte Trustees so detemine.
Unrestricted income comprises fvnds which the tnBtees are free to usp for any purpose in futheranco of
the charttable obiects. Unrestricted funds indude des*3nated fvnds where Ihe trustees. at their disL¥etion,
have created a fund for a specific purpose.
1.3 Income recognition
l income is recognised the charity has entitlement to th8 income. it is prrt>abte that the income Mll
be received and the amcNJnt of income receNaile be measured reliabty.
Donations and legacies are recognlsed wknen Ihe charity has been nOttr￿d Sn wr4ting of both the 8mour)t
and the setuement date.
Dividends are accounted for on an ex4ivi(Jend acwals basi& Int￿e$l on deposits and fixed intsrest
se(xJrities are 8c¢x)unted ft)r on an accruals basis.
1.4 Support and governance costs
The charity does not incur support costs. Govemance costs comprise all costs involving the public
accA)untability of the chaThty arKI its compliance with regulatson and g)C4J practice.
Govemance costs relate lo charitable aclivthes.
1.5 Exp&ndlture rncognltSon
Liabiltties are recognised as expendiiure as soon as there is a legal or (x)nstru¢tive obligation committing
the charity to that expendiiure. it is probable th* Sett￿ment wim be required. and the amouffl of the
obligation can be measured reliabity.
Grafits payable are payments made to third parties in the furtheran￿ of the charitable objects of the Trust.
This is accrued once the recipient has been notif￿ of the grant award.
10-

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For the financial year ended 5 Apnl 2021
Accounting poIIGles
(con￿nued)
1.6 Fixed asset investments
Investsnefits are a form of b8sic finanoal inslnJment arnj are inltially recognised at Iheir transaction value.
Listed investrnerkts are subsequendy measured at their fair value as at the balance sheet date using the
dosing quoted market price. Unlisted investments are sub5equenlly meaSU￿d at fair value. unles5 fair
value cannot be measured reliatAy, in which case they are measured at cost less impairmenL The Trust
does not acquire put options. derivatives or olher CoM￿X finanaal instwments. The statement of financial
a¢tivities indudes the net gains and losses 8rising on revaluati￿ and disposals throughout th8 period.
The main fom) of financial risk fa￿￿ by the charity is that of YO￿t￿ty in equity markets and investment
markets due lo wider economic conditions. the attibAe of investors to invesknent risK and thanges in
sentiment (￿ncernIng equities and wthn parlicLdar sectors or sub*ctots.
1.7 Foreign currencies
Transactions in foreign currenoes are reccrfjnised at the rate of exchan9e at the date of the transaction.
Monetary assets and f￿bilitieS are translated into sterling at the exchange rate on the balanGe sheet date.
Al exchange differences are rerngnised through the statement of financial activities.
1.8 Financial instruments
Financial instruments are dassified and accounted for, acccidirwJ to the substante of the cc￿tractUal
arrangemenl, as financial assets or finanetal liabiSrknes.
1.9 Realised gains and losses
I gains and losses are taken to Ihe Statement of Finanoa Activities as they arise. Realised gains and
losses ￿ investments are calculated as the difference betweet) sales proceeds and their opening carrying
value or their purchase value rf acquired subsequent to the first day of the financial year. Unrealised gains
and losses a￿ t￿l¢u1aled as the d[Ireren￿ belween the fair value at the year end and their carrying value.
Realised and unrealised investment gains and losses are C(￿tsned in the Statement of Financial Activities.
1.10 Taxation
The charity is exempt from taxatM)n under 521 to 536 of the Incon7e Tax Act 2007.
Invgstments
2021
2020
UK fixed interest
UK dividends
UK bank interest
Overseas fixed interest
Overseas dividends
873
1,427
349
14,276
4,865
2,291
2,827
773
21,790
5,891
Investrnent income for the year was attrilxrtable to Ihe Unrestrided IncLYne Fund
11

THE LORNA AND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For the financial year ended 5 Apnl 2021
Other Income
2021
2020
Royalties from YEDA
696.158
2,303,600
By a Deed OIAS￿gnMenI dated 14 August 2019 roy￿lieS due to Yuti Chemaiovsky were formally
assigned to theTrustees unld fijrther notKe
Ralslng Funds
Expenditure on raising fiJnds dursng the year consisted wholly of investment management fees and was
bank tharge$ which a￿ atlributaile to the Unrestricaed Fund.
2021
2020
Bank fees
487
1,229
Analysis of expenditure on charftable activi
2020
ACC￿)untancY ServI￿S
Legal fees
Administrative ¢osts
A￿lit
Independent examination fee
Tnjstee travel expenses
7,059
5,137
3,055
2.400
7.588
10,319
6,000
371
18,251
26.678
Grants and donations
785,089
803,340
26,678
12-

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
NOTES TO THE FINANCIALSTATEMENTS (CONTINUED)
For the financial year ended 5 Apnl 2021
Grants and donations
Grants and donations paid to Charitab￿ causes and instslLrtI￿.
2021
2020
British Immunology Soaety
Universty of Surrey- Maluquer de Motes arwj Gutierrez
Univetsity of Surrey- Mc Vey Pandha
MS Society- Pingen
BSRA- McGettrick arHJ Edwards
Sh8ffield University- Wilson. Toth. Bal￿ntUC￿0 and FO"L*ards
Birmingham Universty- Dhruv Parekh and Davwj Thicket
WHRI- Pe￿ettI and Cooper
20,000
83,500
95,981
106.764
143.790
98,138
142,908
785,089
Investrnents
2021
2020
Quoted invgstmgnts
Fair value brought forward al 6 Aprffl 2tf20
Additions at cost
Disposal prLKeeds
Net gainsllosses on investments
Unrealised gains on investrnents
I.045.￿6
1.601,021
(1,012.595)
7,975
76.458
1,183.985
131,6901
{15,3611
(91,9081
Fair value at 5 Aprfl 2021
1.717.865
1,045,006
Invgstmènts at fair valuè conslst ol:
UK holdlngs
Fixed interesl securiti8S
Quoted equities
784,293
179,449
822.938
88,357
Overseas holdings
Fixed interest securities
QiJot8d equities
428,477
325.646
133.711
Fair value al 5 Awil 2021
1,717,865
1.045.006
The net losses on Invesknent assels during the per*Jd were attributable to the Unrestrictsd Fund
13-

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
NOTES TO THE HNANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2021
Debtors
2021
2020
Amounts falling due wlthin one year.
Accrued Ir￿
Accrued irm from YEDA
349
458,651
351.522
351,522
459,000
Creditors: amounts falling due within one year
2021
2020
D¢￿?tiOnS grants
Independent examination fee
Audit fee
AccoLFnlanGy fee
735,215
3,000
6,000
6,900
6,000
2,400
751.115
8.400
Related party transactlons
The trustees are authorised by Ihe Trust Deed lo pay wofess*)nal clwrgeg to trustees engaged in a
professional capatity on ts instrwfiorF ofthe other trustees.
14-

THE LORNAAND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH
FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 5APRIL 2021
10 Financial assets and liabilities
The folh)wing are financial assets and liats'lities that qualify as basic financial instruments and are
initially recryJnised at tr8nsactw)n value and subsequenty measured at their fair value.
Financiai assets
2021
2020
Accrued investment income
Accrued income from YEDA
36.570
351.523
349
458,651
388.093
459.000
Flnandal Llabilities
Donations and grants payable
735,214
The f(Alowing are financial assets that qUa￿fy as b*ic finanoal instruments arKI are inibally recognised
at their transact￿ value and subsequenuy measured at their fair value as al the b￿anL% sheet date
using the dosing quoted market price.
Financial assets
Investsnents
1,717,865
1,045,006
15-